(300204) Shu Taishen: to disclose the Chinese report
Announcement date: 2024-06-28 00:00:00
(300204) Shu Taishen: to disclose the Chinese report
(300204) Shutaishen: First quarter report of 2024
Announcement date: April 25, 2024 00:00:00
(300204) Shutaishen: First quarter report of 2024 Shutaishen now releases the first quarter report of 2024
(300204) Shu Taishen: Quarterly report to be disclosed
Announcement date: 2024-03-29 00:00:00
(300204) Shu Taishen: Quarterly report to be disclosed
(300204) Shu Taishen: hold 2023 annual general meeting of shareholders
Announcement date: 2024-03-26 00:00:00
1.00 Proposal on the 2023 Work Report of the Board of Directors of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd 2.00 Proposal on the 2023 Work Report of the Board of Supervisors of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd 3.00 Proposal on the 2023 Financial Final Account Report of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd 4.00 Proposal on the 2023 Annual Report and Summary of Annual Report of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd 5.00 Proposal on 2023 Profit Distribution Plan of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd 6.00 Proposal on Renewing the Employment of Accounting Firm 7.00 Proposal on Remuneration Plan of Directors and Supervisors in 2024 8.00 Proposal on the Prediction of Connected Transactions of the Company and Subsidiaries in 2024 9.00 Proposal on Absorption and Merger of Wholly owned Subsidiary De Feng Rui 10.00 Proposal on Absorption and Merger of Wholly owned Subsidiary Zhejiang Shutaishen
(300204) Shu Taishen: Summary of 2023 Annual Report
Announcement date: 2024-03-26 00:00:00
(300204) Shu Taishen: Summary of 2023 Annual Report Shutaishen now releases the summary of 2023 annual report
(300204) Shu Taishen: annual report to be disclosed
Announcement date: 2023-12-29 00:00:00
(300204) Shu Taishen: annual report to be disclosed
(300204) Shu Taishen: Announcement on Extending the Validity Period of the Resolution of the General Meeting of Shareholders to Issue Shares to Specific Objects in 2022 and the Validity Period of the Authorization of the General Meeting of Shareholders to the Board of Directors
Announcement date: 2023-12-27 00:00:00
(300204) Shu Taishen: Announcement on Extending the Validity Period of the Resolution of the General Meeting of Shareholders to Issue Shares to Specific Objects in 2022 and the Validity Period of the Authorization of the General Meeting of Shareholders to the Board of Directors Shutaishen now releases the announcement on extending the validity period of the resolution of the general meeting of shareholders of the company to issue shares to specific targets in 2022 and the validity period of the authorization of the general meeting of shareholders to the board of directors
(300204) Shu Taishen: Securities up to 15%
Announcement date: 2023-11-21 00:00:00
Top 5 purchase amount: Name of business department Purchase amount (yuan) Sales amount (yuan) Huaxin Securities Co., Ltd. Shanghai Jinshan Securities Business Department 17709874.00 18712.00 Huaxin Securities Co., Ltd. Shenzhen Yitian Road Securities Business Department 12961676.00 Huaxin Securities Co., Ltd. Shanghai Caoxi North Road Securities Business Department 12859756.00 Huaxin Securities Co., Ltd. Shanghai Branch 12179567.00 250445.00 Shenzhen Branch of East Asia Qianhai Securities Co., Ltd. 10445526.00 Top 5 selling amount: Name of business department Purchase amount (yuan) Sales amount (yuan) Special for Shenzhen Stock Connect 5802288.00 21926250.00 Huzhou Securities Business Department of China Galaxy Securities Co., Ltd. 1130.00 5554869.00 Guosen Securities Co., Ltd. Guangzhou Dongfeng Middle Road Securities Business Department 59368.00 4368999.00 Guotai Jun'an Securities Co., Ltd. Zhengzhou Huanghe Road Securities Business Department 77465.00 3426589.00 Special for institutions 2429739.00 3377088.00
(300204) Shu Taishen: Hold the 3rd Extraordinary General Meeting of Shareholders in 2023
Announcement date: 2023-10-26 00:00:00
1.00 Proposal on Closing the Initial Public Offering and Permanently Replenishing the Surplus Raised Capital to Working Capital 2.00 Proposal on Closing of Some Over raised Projects and Permanent Replenishment of Working Capital by Using Some Over raised Funds 3.00 Proposal on the Increase of 2023 Daily Related Transaction Forecast of the Company and Subsidiaries 4.00 Proposal on Change of Registered Capital of the Company 5.00 Proposal on Amending the Articles of Association and Related Systems 5.01 Proposal on Amending the Articles of Association of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd 5.02 Proposal on Amending the Administrative Measures for Foreign Investment 5.03 Proposal on Amending the Working System of Independent Directors 5.04 Proposal on Amending the External Guarantee Management System
(300204) Shutaishen: report for the third quarter of 2023
Announcement date: 2023-10-26 00:00:00
(300204) Shutaishen: report for the third quarter of 2023 Shutaishen now releases the third quarter report of 2023
(300204) Shu Taishen: Quarterly report to be disclosed
Announcement date: 2023-09-28 00:00:00
(300204) Shu Taishen: Quarterly report to be disclosed
(300204) Shu Taishen: Announcement on the vesting results of the third vesting period of the first grant of the 2020 equity incentive plan and the listing of shares
Announcement date: 2023-09-21 00:00:00
(300204) Shu Taishen: Announcement on the vesting results of the third vesting period of the first grant of the 2020 equity incentive plan and the listing of shares Shutaishen now releases the announcement on the vesting results of the third vesting period of the first grant of the 2020 equity incentive plan and the listing of shares
(300204) Shu Taishen: Announcement on the vesting results of the second vesting period of the reserved part of the 2020 equity incentive plan and the listing of shares
Announcement date: 2023-09-08 00:00:00
(300204) Shu Taishen: Announcement on the vesting results of the second vesting period of the reserved part of the 2020 equity incentive plan and the listing of shares Shutaishen now releases the announcement on the results of the second vesting period of the reserved part of the 2020 equity incentive plan and the listing of shares
(300204) Shu Taishen: Summary of 2023 Semi annual Report
Announcement date: 2023-08-29 00:00:00
(300204) Shu Taishen: Summary of 2023 Semi annual Report Shu Taishen is now releasing the summary of the semi annual report of 2023
(300204) Shu Taishen: to disclose the Chinese report
Announcement date: 2023-06-30 00:00:00
(300204) Shu Taishen: to disclose the Chinese report
(300204) Shu Taishen: Hold the 2nd Extraordinary General Meeting of Shareholders in 2023
Announcement date: 2023-06-13 00:00:00
1.00 Proposal on Termination of Some Funded Projects
(300204) Shu Taishen: Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2023
Announcement date: 2023-06-13 00:00:00
(300204) Shu Taishen: Notice on Convening the Second Extraordinary General Meeting of Shareholders in 2023 Shu Taishen hereby issues the notice on convening the second extraordinary general meeting of shareholders in 2023
(300204) Shutaishen: First quarter report of 2023
Announcement date: April 26, 2023 00:00:00
(300204) Shutaishen: First quarter report of 2023 Shutaishen now releases the first quarter report of 2023
(300204) Shu Taishen: Quarterly report to be disclosed
Announcement date: 2023-03-31 00:00:00
(300204) Shu Taishen: Quarterly report to be disclosed
(300204) Shu Taishen: hold 2022 annual general meeting of shareholders
Announcement date: March 21, 2023 00:00:00
1.00 Proposal on the 2022 Work Report of the Board of Directors of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd 2.00 Proposal on the 2022 Work Report of the Board of Supervisors of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd 3.00 Proposal on the 2022 Financial Final Account Report of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd 4.00 Proposal on the 2022 Annual Report and Summary of Annual Report of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd 5.00 Proposal on the 2022 Profit Distribution Plan of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd 6.00 Proposal on Renewing the Employment of Accounting Firm 7.00 Proposal on Remuneration Plan of Directors and Supervisors in 2023 8.00 Proposal on the Prediction of Connected Transactions of the Company and Subsidiaries in 2023 9.00 Amendment to the Articles of Association of Shutaishen (Beijing) Biological Pharmaceutical Co., Ltd
